Jacobs Levy Equity Management
RCKT icon

Jacobs Levy Equity Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Jacobs Levy Equity Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.75M Buy
1,974,896
+1,558,363
+374% +$5.18M 0.02% 383
2026
Q1 		$1.49M Buy
+416,533
New +$1.66M 0.01% 636

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jacobs Levy Equity Management's RCKT Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Rocket Pharmaceuticals (RCKT) stake by 374% in Q2 2026, buying an estimated $5.18M and bringing the position to 1,974,896 shares worth $6.75M. The position accounts for 0.02% of the portfolio, ranked #383.

Jacobs Levy Equity Management first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Jacobs Levy Equity Management held 1,974,896 shares of Rocket Pharmaceuticals worth $6.75M as of Q2 2026.
  • Jacobs Levy Equity Management bought 1,558,363 Rocket Pharmaceuticals shares in Q2 2026, an estimated $5.18M.
  • Rocket Pharmaceuticals made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #383 holding.
  • Jacobs Levy Equity Management first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.